STERIS plc (STE)
USD 207.01
(-1.19%)
USD 207.01
(-1.19%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 3.38 Billion USD | 12.08% |
| 2023 | 3.01 Billion USD | -3.4% |
| 2022 | 3.12 Billion USD | 89.32% |
| 2021 | 1.65 Billion USD | 43.46% |
| 2020 | 1.15 Billion USD | -2.76% |
| 2019 | 1.18 Billion USD | -10.09% |
| 2018 | 1.31 Billion USD | -10.98% |
| 2017 | 1.47 Billion USD | -5.7% |
| 2016 | 1.56 Billion USD | 151.55% |
| 2015 | 623.25 Million USD | 26.3% |
| 2014 | 493.48 Million USD | 0.24% |
| 2013 | 492.29 Million USD | 134.42% |
| 2012 | 210 Million USD | 0.0% |
| 2011 | 210 Million USD | 0.0% |
| 2010 | 210 Million USD | 0.0% |
| 2009 | 210 Million USD | 16.68% |
| 2008 | 179.98 Million USD | 77.19% |
| 2007 | 101.57 Million USD | -12.61% |
| 2006 | 116.23 Million USD | 6.48% |
| 2005 | 109.16 Million USD | -3.51% |
| 2004 | 113.13 Million USD | 83.48% |
| 2003 | 61.66 Million USD | -47.25% |
| 2002 | 116.89 Million USD | -43.55% |
| 2001 | 207.08 Million USD | -23.45% |
| 2000 | 270.51 Million USD | 20.93% |
| 1999 | 223.7 Million USD | 44.25% |
| 1998 | 155.07 Million USD | 331.97% |
| 1997 | 35.9 Million USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| 1994 | - USD | 0.0% |
| 1993 | - USD | 0.0% |
| 1992 | - USD | -100.0% |
| 1991 | 700 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 3.5 Billion USD | 4.24% |
| 2024 Q1 | 2.86 Billion USD | -5.25% |
| 2024 Q2 | 3.36 Billion USD | 17.7% |
| 2024 Q4 | 3.38 Billion USD | -3.59% |
| 2024 FY | 3.38 Billion USD | 12.08% |
| 2023 Q3 | 3.09 Billion USD | -3.3% |
| 2023 FY | 3.01 Billion USD | -3.4% |
| 2023 Q4 | 3.01 Billion USD | -2.51% |
| 2023 Q2 | 3.2 Billion USD | 5.58% |
| 2023 Q1 | 3.03 Billion USD | -2.94% |
| 2022 Q4 | 3.12 Billion USD | -1.59% |
| 2022 Q2 | 3.42 Billion USD | -10.86% |
| 2022 Q1 | 3.83 Billion USD | 132.56% |
| 2022 FY | 3.12 Billion USD | 89.32% |
| 2022 Q3 | 3.17 Billion USD | -7.2% |
| 2021 FY | 1.65 Billion USD | 43.46% |
| 2021 Q3 | 1.71 Billion USD | 67.87% |
| 2021 Q4 | 1.65 Billion USD | -3.66% |
| 2021 Q1 | 1.02 Billion USD | -11.16% |
| 2021 Q2 | 1.02 Billion USD | -0.16% |
| 2020 Q3 | 1.26 Billion USD | 6.15% |
| 2020 Q2 | 1.18 Billion USD | -1.88% |
| 2020 Q1 | 1.21 Billion USD | 2.26% |
| 2020 Q4 | 1.15 Billion USD | -8.7% |
| 2020 FY | 1.15 Billion USD | -2.76% |
| 2019 Q1 | 1.32 Billion USD | 0.31% |
| 2019 Q4 | 1.18 Billion USD | -5.06% |
| 2019 FY | 1.18 Billion USD | -10.09% |
| 2019 Q2 | 1.26 Billion USD | -3.97% |
| 2019 Q3 | 1.24 Billion USD | -1.69% |
| 2018 Q1 | 1.49 Billion USD | 1.22% |
| 2018 Q3 | 1.42 Billion USD | -1.75% |
| 2018 Q4 | 1.31 Billion USD | -7.33% |
| 2018 FY | 1.31 Billion USD | -10.98% |
| 2018 Q2 | 1.44 Billion USD | -3.42% |
| 2017 Q1 | 1.55 Billion USD | -1.02% |
| 2017 Q3 | 1.5 Billion USD | 0.19% |
| 2017 Q4 | 1.47 Billion USD | -1.9% |
| 2017 FY | 1.47 Billion USD | -5.7% |
| 2017 Q2 | 1.5 Billion USD | -3.07% |
| 2016 Q2 | 829.81 Million USD | 20.94% |
| 2016 Q1 | 686.16 Million USD | 10.09% |
| 2016 Q3 | 1.63 Billion USD | 97.57% |
| 2016 Q4 | 1.56 Billion USD | -4.37% |
| 2016 FY | 1.56 Billion USD | 151.55% |
| 2015 Q2 | 619.95 Million USD | -5.89% |
| 2015 FY | 623.25 Million USD | 26.3% |
| 2015 Q1 | 658.74 Million USD | 33.49% |
| 2015 Q4 | 623.25 Million USD | 2.06% |
| 2015 Q3 | 610.68 Million USD | -1.5% |
| 2014 Q3 | 474.74 Million USD | -6.64% |
| 2014 Q2 | 508.52 Million USD | -1.01% |
| 2014 Q4 | 493.48 Million USD | 3.95% |
| 2014 Q1 | 513.7 Million USD | 4.35% |
| 2014 FY | 493.48 Million USD | 0.24% |
| 2013 Q2 | 434.34 Million USD | 106.83% |
| 2013 FY | 492.29 Million USD | 134.42% |
| 2013 Q3 | 520.89 Million USD | 19.93% |
| 2013 Q4 | 492.29 Million USD | -5.49% |
| 2013 Q1 | 210 Million USD | 0.0% |
| 2012 FY | 210 Million USD | 0.0% |
| 2012 Q4 | 210 Million USD | 0.0% |
| 2012 Q3 | 210 Million USD | 0.0% |
| 2012 Q2 | 210 Million USD | 0.0% |
| 2012 Q1 | 210 Million USD | 0.0% |
| 2011 Q3 | 210 Million USD | 0.0% |
| 2011 FY | 210 Million USD | 0.0% |
| 2011 Q1 | 210 Million USD | 0.0% |
| 2011 Q2 | 210 Million USD | 0.0% |
| 2011 Q4 | 210 Million USD | 0.0% |
| 2010 Q2 | 210 Million USD | 0.0% |
| 2010 FY | 210 Million USD | 0.0% |
| 2010 Q4 | 210 Million USD | -32.26% |
| 2010 Q3 | 310 Million USD | 47.62% |
| 2010 Q1 | 210 Million USD | 0.0% |
| 2009 Q3 | 210.3 Million USD | -16.15% |
| 2009 Q1 | 178.26 Million USD | -0.96% |
| 2009 FY | 210 Million USD | 16.68% |
| 2009 Q4 | 210 Million USD | -0.14% |
| 2009 Q2 | 250.8 Million USD | 40.69% |
| 2008 FY | 179.98 Million USD | 77.19% |
| 2008 Q1 | 110.55 Million USD | 8.84% |
| 2008 Q2 | 125.59 Million USD | 13.6% |
| 2008 Q3 | 132.92 Million USD | 5.84% |
| 2008 Q4 | 179.98 Million USD | 35.4% |
| 2007 Q1 | 189.69 Million USD | 63.2% |
| 2007 FY | 101.57 Million USD | -12.61% |
| 2007 Q4 | 101.57 Million USD | -19.54% |
| 2007 Q3 | 126.24 Million USD | -14.95% |
| 2007 Q2 | 148.43 Million USD | -21.75% |
| 2006 Q1 | 128.88 Million USD | 18.06% |
| 2006 Q4 | 116.23 Million USD | 8.12% |
| 2006 FY | 116.23 Million USD | 6.48% |
| 2006 Q3 | 107.5 Million USD | -1.12% |
| 2006 Q2 | 108.72 Million USD | -15.64% |
| 2005 Q3 | 105.6 Million USD | -3.08% |
| 2005 FY | 109.16 Million USD | -3.51% |
| 2005 Q1 | 106.85 Million USD | -5.56% |
| 2005 Q2 | 108.95 Million USD | 1.97% |
| 2005 Q4 | 109.16 Million USD | 3.37% |
| 2004 Q3 | 113.6 Million USD | 9.3% |
| 2004 FY | 113.13 Million USD | 83.48% |
| 2004 Q1 | 117.23 Million USD | 90.11% |
| 2004 Q2 | 103.93 Million USD | -11.34% |
| 2004 Q4 | 113.13 Million USD | -0.41% |
| 2003 Q2 | 101.98 Million USD | -4.35% |
| 2003 Q4 | 61.66 Million USD | -29.67% |
| 2003 Q1 | 106.62 Million USD | -8.79% |
| 2003 Q3 | 87.68 Million USD | -14.02% |
| 2003 FY | 61.66 Million USD | -47.25% |
| 2002 FY | 116.89 Million USD | -43.55% |
| 2002 Q4 | 116.89 Million USD | -20.77% |
| 2002 Q2 | 167.56 Million USD | -2.28% |
| 2002 Q3 | 147.53 Million USD | -11.95% |
| 2002 Q1 | 171.47 Million USD | -17.2% |
| 2001 Q3 | 220.9 Million USD | -13.85% |
| 2001 FY | 207.08 Million USD | -23.45% |
| 2001 Q4 | 207.08 Million USD | -6.25% |
| 2001 Q1 | 257.51 Million USD | -4.81% |
| 2001 Q2 | 256.4 Million USD | -0.43% |
| 2000 Q1 | 258.7 Million USD | 15.65% |
| 2000 Q4 | 270.51 Million USD | 1.05% |
| 2000 Q2 | 268.3 Million USD | 3.71% |
| 2000 FY | 270.51 Million USD | 20.93% |
| 2000 Q3 | 267.7 Million USD | -0.22% |
| 1999 Q2 | 204.5 Million USD | 31.89% |
| 1999 FY | 223.7 Million USD | 44.25% |
| 1999 Q1 | 155.05 Million USD | -0.02% |
| 1999 Q4 | 223.7 Million USD | 4.58% |
| 1999 Q3 | 213.9 Million USD | 4.6% |
| 1998 Q4 | 155.07 Million USD | -0.14% |
| 1998 Q1 | 35.85 Million USD | -0.13% |
| 1998 Q2 | 159.52 Million USD | 344.94% |
| 1998 Q3 | 155.3 Million USD | -2.65% |
| 1998 FY | 155.07 Million USD | 331.97% |
| 1997 Q1 | 100.3 Million USD | 0.0% |
| 1997 Q2 | 1 Million USD | -99.0% |
| 1997 Q3 | 44.5 Million USD | 4350.0% |
| 1997 FY | 35.9 Million USD | 0.0% |
| 1997 Q4 | 35.9 Million USD | -19.33% |
| 1996 FY | - USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1995 Q2 | 1.5 Million USD | 0.0% |
| 1995 Q3 | - USD | -100.0% |
| 1995 Q4 | - USD | 0.0% |
| 1995 Q1 | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| 1994 Q4 | - USD | 0.0% |
| 1994 Q3 | - USD | 0.0% |
| 1994 FY | - USD | 0.0% |
| 1994 Q1 | - USD | 0.0% |
| 1994 Q2 | - USD | 0.0% |
| 1993 Q2 | - USD | 0.0% |
| 1993 FY | - USD | 0.0% |
| 1993 Q1 | - USD | 0.0% |
| 1993 Q4 | - USD | 0.0% |
| 1993 Q3 | - USD | 0.0% |
| 1992 Q4 | - USD | 0.0% |
| 1992 FY | - USD | -100.0% |
| 1991 Q4 | 700 Thousand USD | 0.0% |
| 1991 FY | 700 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Abbott Laboratories | 15.87 Billion USD | 78.686% |
| Allurion Technologies Inc. | 41.85 Million USD | -7982.679% |
| Artivion, Inc. | 359.34 Million USD | -841.492% |
| Avanos Medical, Inc. | 209.1 Million USD | -1517.966% |
| Butterfly Network, Inc. | 25.02 Million USD | -13418.068% |
| Butterfly Network, Inc. | 25.02 Million USD | -13418.068% |
| Bio-Rad Laboratories, Inc. | 1.4 Billion USD | -140.642% |
| Boston Scientific Corporation | 9.49 Billion USD | 64.358% |
| Perspective Therapeutics, Inc. | - USD | -Infinity% |
| CONMED Corporation | 991.25 Million USD | -241.302% |
| Edwards Lifesciences Corporation | 694.9 Million USD | -386.857% |
| Paragon 28, Inc. | 112.03 Million USD | -2919.876% |
| Glaukos Corporation | 383.73 Million USD | -781.635% |
| Globus Medical, Inc. | 520.4 Million USD | -550.104% |
| Inspire Medical Systems, Inc. | 24.84 Million USD | -13516.546% |
| Integer Holdings Corporation | 1.04 Billion USD | -225.006% |
| Medtronic plc | 26.04 Billion USD | 87.011% |
| Nevro Corp. | 221.82 Million USD | -1425.138% |
| Owlet, Inc. | 15.21 Million USD | -22134.273% |
| Penumbra, Inc. | 234.34 Million USD | -1343.682% |
| Vicarious Surgical Inc. | 14.83 Million USD | -22709.918% |
| Smith & Nephew plc | 3.08 Billion USD | -9.701% |
| Sonendo, Inc. | 40.35 Million USD | -8284.345% |
| Stryker Corporation | 12.99 Billion USD | 73.966% |
| Vapotherm, Inc. | 112.39 Million USD | -2910.149% |
| Zimmer Biomet Holdings, Inc. | 5.99 Billion USD | 43.569% |